- Home
- AMPL vs TVTX Comparison
AMPL vs TVTX Comparison
Compare AMPL & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- TVTX
- Stock Information
- Founded
- AMPL 2012
- TVTX 2008
- Country
- AMPL United States
- TVTX United States
- Employees
- AMPL N/A
- TVTX N/A
- Industry
- AMPL EDP Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMPL Technology
- TVTX Health Care
- Exchange
- AMPL Nasdaq
- TVTX Nasdaq
- Market Cap
- AMPL 1.7B
- TVTX 1.5B
- IPO Year
- AMPL 2021
- TVTX N/A
- Fundamental
- Price
- AMPL $11.53
- TVTX $16.94
- Analyst Decision
- AMPL Buy
- TVTX Strong Buy
- Analyst Count
- AMPL 10
- TVTX 16
- Target Price
- AMPL $13.70
- TVTX $33.40
- AVG Volume (30 Days)
- AMPL 1.5M
- TVTX 1.4M
- Earning Date
- AMPL 08-06-2025
- TVTX 08-06-2025
- Dividend Yield
- AMPL N/A
- TVTX N/A
- EPS Growth
- AMPL N/A
- TVTX N/A
- EPS
- AMPL N/A
- TVTX N/A
- Revenue
- AMPL $316,571,000.00
- TVTX $333,865,000.00
- Revenue This Year
- AMPL $12.78
- TVTX $71.61
- Revenue Next Year
- AMPL $10.79
- TVTX $43.45
- P/E Ratio
- AMPL N/A
- TVTX N/A
- Revenue Growth
- AMPL 9.93
- TVTX 87.94
- 52 Week Low
- AMPL $7.55
- TVTX $8.09
- 52 Week High
- AMPL $14.88
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- AMPL 40.15
- TVTX 61.06
- Support Level
- AMPL $11.37
- TVTX $15.60
- Resistance Level
- AMPL $14.49
- TVTX $17.46
- Average True Range (ATR)
- AMPL 0.70
- TVTX 0.79
- MACD
- AMPL -0.10
- TVTX 0.14
- Stochastic Oscillator
- AMPL 6.77
- TVTX 78.76
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.